As a part of our philosophy to build sustainable and scalable business model, Ajanta Pharma set its eye on entering the world's largest and most stringent pharmaceutical market - USA. We carved out select product portfolio, which include complex technology products to get the competitive advantage in the market place. We have also made substantial investments in our R&D facilities and thereby acquired required technical and regulatory expertise to penetrate the market.
In our quest for expansion in the regulated markets, we expect US market to be our key growth driver in the coming years. With an objective of building a critical size in the marketplace, many important programs are on the cards like investments in R&D, Manufacturing, Team, etc. Our products are already available on the shelf in US through our subsidiary, located in New Jersey, the hub of pharma industry in USA.
As on 31st March 2021, Ajanta has 36 ANDA approvals which are commercialised. And we are awaiting US FDA approval for 15 ANDAs. Company plans to file 10-12 ANDAs during the current financial year.